Evidence map›Paper›PMID 35935935›Full record

ArticleFrontiers in immunology2022

Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.

Henrik Pedersen, Rasmus Kjeldsen Jensen, Annette Gudmann Hansen, Steen Vang Petersen, Steffen Thiel, Nick Stub Laursen, Gregers Rom Andersen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Henrik PedersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Rasmus Kjeldsen JensenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Annette Gudmann HansenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Steen Vang PetersenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Steffen ThielDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Nick Stub LaursenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Gregers Rom AndersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Aarhus University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is a part of the innate immune system, where it labels intruding pathogens as well as dying host cells for clearance. If complement regulation is compromised, the system may contribute to pathogenesis. The proteolytic fragment C3b of complement component C3, is the pivot point of the complement system and provides a scaffold for the assembly of the alternative pathway C3 convertase that greatly amplifies the initial complement activation. This makes C3b an attractive therapeutic target. We previously described a nanobody, hC3Nb1 binding to C3 and its degradation products. Here we show, that extending the N-terminus of hC3Nb1 by a Glu-Trp-Glu motif renders the resulting EWE-hC3Nb1 (EWE) nanobody specific for C3 degradation products. By fusing EWE to N-terminal CCP domains from complement Factor H (FH), we generated the fusion proteins EWEnH and EWEµH. In contrast to EWE, these fusion proteins supported Factor I (FI)-mediated cleavage of human and rat C3b. The EWE, EWEµH, and EWEnH proteins bound C3b and iC3b with low nanomolar dissociation constants and exerted strong inhibition of alternative pathway-mediated deposition of complement. Interestingly, EWEnH remained soluble above 20 mg/mL. Combined with the observed reactivity with both human and rat C3b as well as the ability to support FI-mediated cleavage of C3b, this features EWEnH as a promising candidate for

Indexed as

Complement C3Complement C3bAnimalsComplement ActivationComplement C3-C5 ConvertasesComplement C3 Convertase, Alternative PathwayFibrinogenHumansRatsComplement C3Complement C3bComplement C3-C5 ConvertasesComplement C3 Convertase, Alternative PathwayFibrinogenalternative pathwaycomplement systemFactor Hinhibitorsingle-domain antibody

Identifiers

PMID35935935
PMCPMC9352930
OpenAlexW4286447650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.